When it comes to knowledge sometimes you just can't get enough when you are interested in a topic. Over the past six months we have spent a lot of time giving you the most-up-to-date and relevant information on GLP-1 therapy that we could find. We have provided interviews with thought leaders, surveys of your colleagues, Homerun Slides, and patient case studies. Your response to this information has been overwhelming, so to make it easier to find the most popular, cutting-edge articles on GLP-1 therapy, we have put together this Special Edition, Best of GLP-1, for you.

Mark, a 55-year-old white man, was diagnosed with type 2 diabetes 3 years ago. At the time of diagnosis his glycosylated hemoglobin (A1c) level was 7.5%, his body mass index (BMI) was 30 kg/m², and his waist circumference was 45 inches....

Mr. Walker is a 59-year-old Caucasian who presents for evaluation of his type 2 diabetes, discovered 6 months ago by a random glucose measurement of 250 mg/dL using his wife's blood glucose meter....

Mr. Slayton is a 64-year-old African-American referred by his primary care physician for evaluation of his type 2 diabetes. His history with type 2 diabetes includes....

Oxyntomodulin is a gut peptide released in response to a meal. It is synthesized within specialized enteroendocrine cells called L cells. Oxyntomodulin is released from the intestinal L cells 5-10 minutes after ingestion of food in amounts proportional to calorie intake and levels peak 30 minutes after meals. Oxyntomodulins are thought to act as circulating satiety signals by their effects on the appetite centers such as the hypothalamus and brainstem....

Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss....

Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are....

In a special bonus issue of our GLP-1 Special Series, we presented this excellent and informative interview with Dr. Alan Moses, Global CMO, Novo Nordisk. Dr. Moses gave us his take on the latest in GLP-1 technologies as well as a peek at Novo's efforts in developing world-class therapies in the fight against diabetes....

Our publisher, Steve Freed, sat down with Dr. Steven Edelman at the ADA Scientific Sessions in San Diego, and asked, "When should we add the GLP-1 drugs in the progression of diabetes?" and "How comfortable are you with the safety of the GLP-1 drugs?" ...

Leading experts, Anne L. Peters, MD, Ralph A. DeFronzo, MD, Alan J. Garber, MD, PhD, Robert R. Henry, MD, Richard Bergenstal, MD, and others, share their thoughts on GLP-1 therapy....

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin....

ITCA 650, injection-free continuous delivery of GLP-1 therapy, demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI AEs typically associated with this class....

The investigational drug Bydureon used to treat Type 2 diabetes under development by Eli Lilly & Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. failed to meet primary endpoints in a 26-week study....

This week we start a new series of six sets of Homerun Slides covering Incretins....

This week we begin a special series of Homerun Slides on GLP-1's. In this series, we will be covering: physiology of GLP-1; clinical effects of GLP-1r agonists and DPP-4 inhibitors stemming from incretin action; the role of glucagon in glucose intolerance and effects of GLP-1 based drugs on plasma glucagon; and the cardiovascular effects of GLP-1....

GLP-1 multiple actions. In humans it stimulates insulin secretion in a glucose-dependent manner and inhibits glucagon secretion, leading to a reduction in hepatic glucose production (HGP)....